(2E)-N-1,3-benzothiazol-2-yl-3-(4-methoxyphenyl)acrylamide | 850724-26-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (2E)-N-1,3-benzothiazol-2-yl-3-(4-methoxyphenyl)acrylamide
• 英文别名: (E)-N-(benzo[d]thiazol-2-yl)-3-(4-methoxyphenyl)acrylamide；(2E)-N-(1,3-benzothiazol-2-yl)-3-(4-methoxyphenyl)prop-2-enamide；(E)-N-(1,3-benzothiazol-2-yl)-3-(4-methoxyphenyl)prop-2-enamide
• CAS: 850724-26-4
• 化学式: C₁₇H₁₄N₂O₂S
• 分子量: 310.376
• InChiKey: BWMGEUMRYJZGHT-DHZHZOJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  79.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (2-aminophenyl) N-[(E)-3-(4-methoxyphenyl)prop-2-enoyl]carbamodithioate 以75%的产率得到
  参考文献：
  名称：

  ABED, N. M.;SOWELLIM, S. Z.;ELAGAMEY, A. -G. A.;HARB, A. -F. A., REV. PORT. QUIM., 28,(1986) N-4, C. 95-100

  摘要：

  DOI：

文献信息

• Facile synthesis of N-acyl 2-aminobenzothiazoles by NHC-catalyzed direct oxidative amidation of aldehydes
  作者：Sethulekshmy Premaletha、Arghya Ghosh、Sumi Joseph、Santhivardhana Reddy Yetra、Akkattu T. Biju

  DOI：10.1039/c6cc08640c

  日期：——

  A mild, general, and high yielding synthesis of N-acyl 2-aminobenzothiazoles has been demonstrated by the N-heterocyclic carbene (NHC)-organocatalyzed direct amidation of aldehydes with 2-aminobenzothiazoles proceeding via the acyl azolium intermediates....

  N-杂环卡宾（NHC）有机催化醛与2-氨基苯并噻唑的直接酰胺化反应是通过酰基偶氮中间体进行的，该方法温和，常规且高收率地合成了N-酰基2-氨基苯并噻唑....
• N-Acylated and N-Alkylated 2-Aminobenzothiazoles Are Novel Agents That Suppress the Generation of Prostaglandin E2
  作者：Maria A. Theodoropoulou、Anastasia Psarra、Martin Erhardt、Aikaterini Nikolaou、Anna-Dimitra D. Gerogiannopoulou、Dimitra Hadjipavlou-Litina、Daiki Hayashi、Edward A. Dennis、Andrea Huwiler、George Kokotos

  DOI：10.3390/biom12020267

  日期：——

  diseases. We synthesized a series of N-acylated and N-alkylated 2-aminobenzothiazoles and related heterocycles (benzoxazoles and benzimidazoles) and evaluated their ability to suppress the cytokine-stimulated generation of PGE2 in rat mesangial cells. 2-Aminobenzothiazoles, either acylated by the 3-(naphthalen-2-yl)propanoyl moiety (GK510) or N-alkylated by a chain carrying a naphthalene (GK543) or a phenyl

  寻求调节前列腺素 E2 (PGE2) 生成的新药物非常重要，因为这种类花生酸是炎症性疾病的关键因素。我们合成了一系列 N-酰化和 N-烷基化 2-氨基苯并噻唑和相关杂环（苯并恶唑和苯并咪唑），并评估了它们在大鼠系膜细胞中抑制细胞因子刺激的 PGE2 生成的能力。2-氨基苯并噻唑，或者被 3-(萘-2-基)丙酰基部分 (GK510) 酰化，或者被在三个碳原子距离处带有萘 (GK543) 或苯基部分 (GK562) 的链 N-烷基化，在抑制 PGE2 生成方面表现突出，EC50 值范围为 118 nM 至 177 nM。GK510 和 GK543 的体内抗炎活性均高于消炎痛。因此，
• Synthesis of a series of benzothiazole amide derivatives and their biological evaluation as potent hemostatic agents
  作者：Wenqian Nong、Anran Zhao、Jinrui Wei、Hui Cheng、Xuan Luo、Cuiwu Lin

  DOI：10.1039/c7ra13397a

  日期：——

  A series of benzothiazole amide derivatives were synthesized through a facile and efficient method via a nucleophilic acyl substitution reaction between 2-aminobenzothiazole and various cinnamic acid compounds. The obtained products exhibited good thermal stabilities. All compounds were evaluated for their in vitro hemostatic activities using the commercially available standard drug etamsylate as a

  通过2-氨基苯并噻唑与多种肉桂酸化合物的亲核酰基取代反应，通过简便、高效的方法合成了一系列苯并噻唑酰胺衍生物。所得产物表现出良好的热稳定性。使用市售标准药物酚磺乙胺作为阳性对照，评估所有化合物的体外止血活性。结果显示，化合物Q2具有显着的部分凝血活性，在5、10和50 μmol L -1时降低毛细血管通透性，激活凝血酶活性，并且比阳性对照组（酚磺乙胺，高达1283.9倍）具有更强的血小板聚集活性。在纳摩尔范围内）。分子模型研究表明，化合物Q2是一种竞争性凝血酶激活剂。因此， Q2可能是进一步生物筛选和药物分子生成的潜在先导。此外，本文还讨论了所制备化合物的结构-活性关系。
• [EN] BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS<br/>[FR] COMPOSITIONS DE BENZOTHIAZOLE ET DE THIAZOLE'5,5-B!PYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE L'UBIQUITINE LIGASE
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2005037845A1

  公开（公告）日：2005-04-28

  This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a pharmaceutical composition according to the invention.

  这项发明描述了化合物和制药组合物，作为泛素代理抑制剂。该发明的化合物和制药组合物作为抑制泛素化参与的生物化学途径的抑制剂是有用的。该发明还包括使用该发明的化合物和制药组合物治疗需要抑制泛素化的情况。此外，该发明还包括通过使用该发明的制药组合物接触需要抑制泛素化的细胞来抑制细胞内泛素化的方法。
• Benzothiazole compositions and their use as ubiquitin ligase inhibitors
  申请人：Ramesh V. Usha

  公开号：US20050130974A1

  公开（公告）日：2005-06-16

  This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a pharmaceutical composition according to the invention.

  本发明描述了化合物和药物组合物，可用作泛素代理抑制剂。本发明的化合物和药物组合物可用作生物体中涉及泛素化的生化途径的抑制剂。本发明还包括使用本发明的化合物和药物组合物治疗需要抑制泛素化的疾病的方法。此外，本发明还包括通过将本发明的药物组合物接触到需要抑制泛素化的细胞中来抑制细胞泛素化的方法。